These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19759355)

  • 1. Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia.
    Volanakis EJ; Williams RT; Sherr CJ
    Blood; 2009 Nov; 114(20):4451-9. PubMed ID: 19759355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation of the Ink4a-Arf (Cdkn2a) tumor suppressor locus in the initiation and progression of Notch1-driven T cell acute lymphoblastic leukemia.
    Volanakis EJ; Boothby MR; Sherr CJ
    Exp Hematol; 2013 Apr; 41(4):377-86. PubMed ID: 23178376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
    Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
    Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
    Treanor LM; Volanakis EJ; Zhou S; Lu T; Sherr CJ; Sorrentino BP
    Blood; 2011 May; 117(20):5453-62. PubMed ID: 21427293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developmental strategies for evasion of Arf tumor suppression.
    Volanakis EJ; Sherr CJ
    Cell Cycle; 2010 Jan; 9(1):14-5. PubMed ID: 20009580
    [No Abstract]   [Full Text] [Related]  

  • 6. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
    Young FM; Campbell A; Emo KL; Jansson J; Wang PY; Jordan CT; Mullen CA
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):622-30. PubMed ID: 18489987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin C is a haploinsufficient tumour suppressor.
    Li N; Fassl A; Chick J; Inuzuka H; Li X; Mansour MR; Liu L; Wang H; King B; Shaik S; Gutierrez A; Ordureau A; Otto T; Kreslavsky T; Baitsch L; Bury L; Meyer CA; Ke N; Mulry KA; Kluk MJ; Roy M; Kim S; Zhang X; Geng Y; Zagozdzon A; Jenkinson S; Gale RE; Linch DC; Zhao JJ; Mullighan CG; Harper JW; Aster JC; Aifantis I; von Boehmer H; Gygi SP; Wei W; Look AT; Sicinski P
    Nat Cell Biol; 2014 Nov; 16(11):1080-91. PubMed ID: 25344755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
    Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
    Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct sensitivity of CD8+ CD4- and CD8+ CD4+ leukemic cell subpopulations to cyclophosphamide and rapamycin in Notch1-induced T-ALL mouse model.
    Zhang Y; Hua C; Cheng H; Wang W; Hao S; Xu J; Wang X; Gao Y; Zhu X; Cheng T; Yuan W
    Leuk Res; 2013 Nov; 37(11):1592-601. PubMed ID: 24090996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL.
    Jeannet R; Mastio J; Macias-Garcia A; Oravecz A; Ashworth T; Geimer Le Lay AS; Jost B; Le Gras S; Ghysdael J; Gridley T; Honjo T; Radtke F; Aster JC; Chan S; Kastner P
    Blood; 2010 Dec; 116(25):5443-54. PubMed ID: 20829372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice.
    Shank-Calvo JA; Draheim K; Bhasin M; Kelliher MA
    Oncogene; 2006 May; 25(21):3023-31. PubMed ID: 16407836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors.
    Aste-Amézaga M; Zhang N; Lineberger JE; Arnold BA; Toner TJ; Gu M; Huang L; Vitelli S; Vo KT; Haytko P; Zhao JZ; Baleydier F; L'Heureux S; Wang H; Gordon WR; Thoryk E; Andrawes MB; Tiyanont K; Stegmaier K; Roti G; Ross KN; Franlin LL; Wang H; Wang F; Chastain M; Bett AJ; Audoly LP; Aster JC; Blacklow SC; Huber HE
    PLoS One; 2010 Feb; 5(2):e9094. PubMed ID: 20161710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
    Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
    Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1.
    Li X; Gounari F; Protopopov A; Khazaie K; von Boehmer H
    J Exp Med; 2008 Nov; 205(12):2851-61. PubMed ID: 18981238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
    Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
    Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia.
    Robles-Valero J; Lorenzo-Martín LF; Menacho-Márquez M; Fernández-Pisonero I; Abad A; Camós M; Toribio ML; Espinosa L; Bigas A; Bustelo XR
    Cancer Cell; 2017 Nov; 32(5):608-623.e9. PubMed ID: 29136506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1.
    Ashworth TD; Pear WS; Chiang MY; Blacklow SC; Mastio J; Xu L; Kelliher M; Kastner P; Chan S; Aster JC
    Blood; 2010 Dec; 116(25):5455-64. PubMed ID: 20852131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of
    van Oosterwijk JG; Li C; Yang X; Opferman JT; Sherr CJ
    Proc Natl Acad Sci U S A; 2017 Jul; 114(28):7420-7425. PubMed ID: 28652370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance of primary cultured mouse hepatic tumor cells to cellular senescence despite expression of p16(Ink4a), p19(Arf), p53, and p21(Waf1/Cip1).
    Obata M; Imamura E; Yoshida Y; Goto J; Kishibe K; Yasuda A; Ogawa K
    Mol Carcinog; 2001 Sep; 32(1):9-18. PubMed ID: 11568971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavone inhibited proliferation of T-ALL by promoting c-Cbl-induced ubiquitinylation and degradation of Notch1.
    Zhu W; Zhu Y; Xu H; Wang T; Wang J; Meng M; Liu Y; Yan H; Yang Q; Liu P
    Biochem Biophys Res Commun; 2020 Feb; 522(3):684-689. PubMed ID: 31785807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.